- Guidant to buy Cook for up to $3bn; terminated
- Cook licenses rights to paclitaxel from Angiotech
- Boston Scientific licenses paclitaxel rights from Angiotech
- Cook, Guidant develop drug-coated stents; terminated
- Guidant gets co-exclusive rights to Novartis antibiotic
- Boston Scientific acquires Pfizer's Schneider for $2.1bn
- Medtronic acquires Arterial Vascular Engineering for $3.5bn
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.